but serial echocardiograms did not show restrictive cardiomyopathy or progression of the ventricular wall or septal thickness, ruling out cardiac amyloid involvement. Bone marrow biopsy and fat ...

including echocardiography and cardiac MRI (CMR), which can provide diagnostically useful data but cannot easily distinguish one amyloid cardiomyopathy from another. [Ash 2020;6d,7a] The wild type ...

Transthyretin amyloidosis is a progressive, fatal disease that often leads to cardiomyopathy. New research findings on vutrisiran for patients with transthyretin amyloidosis with cardiomyopathy ...

Phase III HELIOS-B trial found that Amvuttra (vutrisiran) also preserved functional capacity and quality of life in patients ...

He had carpal tunnel surgery 2 years prior, in which pathology revealed amyloid. Laboratory studies ... Assess prognosis with echocardiography, including Doppler and strain, serum troponin ...

Surprised? Recommendations From the World Heart Federation on Transthyretin Amyloid Cardiomyopathy The World Heart Federation published a detailed report on transthyretin amyloid cardiomyopathy ...

Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The decision ...

Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet transthyretin cardiac amyloidosis (ATTR-CM)—a serious heart condition ...